Targeted Mass Spectrometry Assays for Diabetes and Obesity Research (TaMADOR) – (UW Diabetes and Metabolism Seminar Series)

8:00-8:30

Light Breakfast
8:30-8:40

Salvatore Sechi, PhD
NIDDK/NIH

History and Purpose of TaMADOR
8:40-8:50

Will Cefalu, M.D.
NIDDK/NIH

Welcome and Introduction (Virtual)
8:50-9:30

Lori Sussel, Ph.D.
University of Colorado Anschutz Medical Campus

Paradoxically: Using proteomics to study non-coding RNAs
9:30-9:55

Mike MacCoss, Ph.D.
University of Washington School of Medicine

Alterations in the plasma extracellular proteome due to treatment of type 1 diabetes
9:55-10:20

Wei-Jun Qian, Ph.D.
Pacific Northwest National Laboratory

Single-islet proteomics maps pseudo-temporal Islet Immune responses and dysfunction in stage 1 T1D
10:20-10:30

Coffee Break
10:30-11:10

Joe Hedrick, Ph.D.
C-PATH Institute

Surrogate endpoint biomarkers for T1D interventions: a regulatory perspective
11:10-11:35

Jessica Becker, MLS(ASCP), M.S.
University of Washington School of Medicine

Interlaboratory validation of an LC-MS/MS assay for glucagon and oxyntomodulin
11:35-12:00

Lorenz Nierves, Ph.D.
Pacific Northwest National Laboratory

MS-based simultaneous quantification of proinsulin and proglucagon processing products to investigate processing mechanisms
12:00-12:45

Lunch
12:45-1:25

Emily Sims, M.D.
Indiana University School of Medicine

Clinical Applications of Prohormone Ratios in Type 1 Diabetes
1:25-1:50

Andy Hoofnagle, MD Ph.D.
University of Washington School of Medicine

Quantification of proinsulin by proteolysis-aided-peptide immunoenrichment-LC-MS/MS
1:50-2:15

Jun Qu, Ph.D.
University of Buffalo

Cross-laboratory validation of a multiplexed LC-MS/MS assay for intact proinsulin, des-31,32/des-64,65 proinsulin, and C-peptide
2:15-2:30

Coffee Break
2:30-2:55

Wei-Jun Qian, Ph.D.
Pacific Northwest National Laboratory

Assessment of intact, des-31,32, and des-64,65 proinsulin as potential biomarkers in cross-sectional and longitudinal samples following T1D diagnosis
2:55-3:20

Sara Shijo, B.S.
University of Washington School of Medicine

Development of proglucagon assays
3:20-4:00

Steven Kahn, M.B., Ch.B.
University of Washington School of Medicine

(1) Beta-cell Peptides: It Does Not Stop With Insulin and C-peptide (2) Taking New Assays Into the “Real World”: Working With the Diabetes Research Centers
4:00-4:20

Panel Discussion: Kuanysh Kabytaev, Des Schatz, Emily Sims, Andy Hoofnagle
C-peptide: Harmonization, clinical utility, and reimbursement requirements